Adam Elhofy

Company: COUR Pharmaceuticals

Job title: VP

Seminars:

Tolerogenic CNP-104 Treatment Regulates Th17 Cells Thereby Slowing PBC Progression and Liver Stiffness 8:30 am

• Demonstrating efficacy across multiple immunological and clinical mechanisms • Highlighting the potential of CNP-105 to be the first disease-modifying treatment for PBC • Delving into the safety and tolerability data supporting ASIT clinical studiesRead more

day: Conference Day One